Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc Ord (OP:AZNCF)

144.50 +3.53 (+2.50%)
Streaming Delayed Price Updated: 11:39 AM EDT, Jun 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Astrazeneca Plc Ord

< Previous 1 2 3 4 5 6 7 8 Next >
Daiichi Sankyo - AstraZeneca's Enhertu Receives Priority Review In US For Lung Cancer
Via Benzinga
After Encouraging Data, Blueprint Medicines Plans Combination Cohort In Tagrisso Resistant Lung Cancer
Blueprint Medicines Corp (NASDAQ: BPMC)  
Via Benzinga
Seagen Wins $42M Patent Claim Against Daiichi In Cancer Drug Case
A jury in Marshall, Texas, awarded Seagen Inc (NASDAQ: SGEN)  
Via Benzinga
AstraZeneca Bets $25M On Preclinical Bispecific Antibody
Via Benzinga
FDA Official Says Frequent COVID-19 Booster Shows Not Sustainable: WSJ
According to a U.S. health regulator, asking people to get COVID-19 boosters frequently wasn't sustainable because of vaccine fatigue, and authorities needed to develop a long-term strategy for... 
Via Benzinga
AstraZeneca's Imfinzi Flunks In Late-Stage Advanced Cervical Cancer Study
Via Benzinga
AstraZeneca's Ultomiris Shows Sustained Improvements In Functional Activities In Neuromuscular Disease
Via Benzinga
Ionis Pharma - AstraZeneca Antisense Medicine Met Its Primary, Secondary Goals To Lower Cholesterol
Ionis Pharmaceuticals Inc (NASDAQ: IONS) and its partner, AstraZeneca Plc (NASDAQ: AZN), have  
Via Benzinga
EMA Recommends Approval Of AstraZeneca's COVID-19 Therapy, Evusheld
EMA's human medicines committee (CHMP) has  
Via Benzinga
AstraZeneca's COVID-19 Vaccine Expected To Win European Approval This Week: Reuters
European Medicines Agency is expected to approve AstraZeneca Plc's (NASDAQ: AZN) antibody-based COVID-19 vaccine for preventing COVID-19 infections,  
Via Benzinga
Bristol Myers Sues AstraZeneca Over PD-L1 Cancer Drug Patents
Bristol Myers Squibb Co (NYSE: BMY) claims that AstraZeneca Plc's (NASDAQ: AZN) PD-L1 inhibitor, Imfinzi, infringed on at least eight patents in a newly filed complaint. 
Via Benzinga
AstraZeneca's COVID-19 Antibody Neutralizes Omicron Sub-variants, Lab Study Shows
AstraZeneca Plc's (NASDAQ: AZN) antibody-based cocktail to prevent and treat COVID-19 retained  
Via Benzinga
AstraZeneca Mulls Ditching US Approval For Its COVID-19 Vaccine: FT
Citing AstraZeneca Plc's (NASDAQ: AZN) head of research and development, the Financial Times reported that the Company  
Via Benzinga
AstraZeneca Settles Ultomiris-Related Patent Litigation With Chugai
Alexion Pharmaceuticals, a unit of AstraZeneca plc (NASDAQ: AZN), has entered into a settlement agreement with Chugai Pharmaceutical Co Ltd, resolving all patent disputes related to Ultomiris... 
Via Benzinga
AstraZeneca's COVID-19 Therapy Approved In Britain As Preventive Option
Britain's Medicines and Healthcare products Regulatory Agency (MHRA)  
Via Benzinga
Europe Kickstarts Reviewing AstraZeneca Application For Its COVID Antibody
Via Benzinga
White House Warns It Cannot Afford COVID-19 Related Solutions If Cases Increase: FT
The White House says that the U.S. is running out of money to pay for COVID-19 vaccines, tests, and treatments, making it unprepared for any rising cases in the future. 
Via Benzinga
Merck-AstraZeneca Stop Keytruda/Lynparza Combo Trial In Prostate Cancer Patients
Merck & Co Inc (NYSE: MRK) will stop the Phase 3 KEYLYNK-010 trial investigating Keytruda combined with Lynparza for metastatic castration-resistant prostate cancer (mCRPC). 
Via Benzinga
FDA Declines To Approve AstraZeneca's Asthma Treatment For Chronic Nasal Condition
The FDA has declined to approve AstraZeneca Plc's (NASDAQ: AZN) asthma medicine, Fasenra (benralizumab), to treat chronic rhinosinusitis with nasal polyps, a... 
Via Benzinga
AstraZeneca-Merck's Lynparza Wins FDA Approval For Early-Stage Breast Cancer
The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) cancer drug, jointly developed with Merck & Co Inc (NYSE: MRK) to treat patients with early-... 
Via Benzinga
AstraZeneca-Sanofi's Nirsevimab Shows 75% Efficacy Against RSV In Healthy Infants
AstraZeneca Plc (NASDAQ: AZN) and Sanofi SA (NASDAQ: SNY) have shared detailed results from the MELODY Phase 3 trial evaluating nirsevimab in respiratory... 
Via Benzinga
AstraZeneca, GSK's COVID-19 Therapies Lose Efficacy Against Omicron's Subvariants
The FDA authorized an increased dose in the case of AstraZeneca Plc's (NASDAQ: AZN) pre-exposure prophylaxis drug Evusheld (tixagevimab and cilgavimab).... 
Via Benzinga
Blood Clot Risk After First AstraZeneca COVID-19 Shot Very Small - UK Study Shows
A large study into rare blood clots linked with AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine found between one and three cases per million, and only after... 
Via Benzinga
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly... 
Via Benzinga
AstraZeneca's Enhertu Meets Primary Endpoint In HER2-Low Breast Cancer Setting
AstraZeneca plc (NASDAQ: AZN) said that Enhertu prolonged survival and slowed the progression of metastatic breast cancer with low levels of a protein known as HER2... 
Via Benzinga
GSK Halts Late-Stage RSV Vaccine Trial In Pregnant Women
GlaxoSmithKline plc (NYSE: GSK) has paused a late-stage trial of its respiratory syncytial virus (RSV) vaccine candidate in pregnant women based on safety... 
Via Benzinga
Short Shelf Life Of AstraZeneca's COVID-19 Shot Entangles Vaccine Rollout In Poorer Nations: Reuters
According to officials and internal World Health Organization documents reviewed by Reuters, the relatively short shelf life of AstraZeneca Plc's (NASDAQ: AZN)... 
Via Benzinga
Why Are AstraZeneca Shares Trading Higher Today
Adding AstraZeneca Plc's (NASDAQ: AZN) Lynparza to Johnson & Johnson's (NYSE: JNJ) Zytiga (abiraterone) extended the time to live without disease... 
Via Benzinga
AstraZeneca Records Bumper COVID-19 Vaccine Sales Of ~$4B In FY21
AstraZeneca Plc's (NASDAQ: AZN) total revenue jumped 63% Y/Y to $12.0 
Via Benzinga
AstraZeneca Dumps Off Mid-Stage Cardiovascular Drug To Regio Biosciences
AstraZeneca plc (NASDAQ: AZN) has granted  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.